Notice of Change in Application Due Date for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"
Notice Number:
NOT-HL-20-811

Key Dates

Release Date:

August 21, 2020

Related Announcements

RFA-HL-21-013

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to alert potential applicants to a change in key dates for RFA-HL-21-013, "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)". Changes are shown in italics below.

Current dates:

Open Date (Earliest Submission Date)

June 24, 2020

Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

July 24, 2020, June 1, 2021, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

December 2020, October 2022, January 2023

Advisory Council Review

January 2021, January 2022, January 2023

Earliest Start Date

April 2021

Expiration Date

June 2, 2022


Revised dates (in italics):

Open Date (Earliest Submission Date)

June 24, 2020

Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

July 24, 2020, March 19, 2021, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

December 2020, April 2021, January 2023

Advisory Council Review

January 2021, May 2021, January 2023

Earliest Start Date

April 2021, August 2021, April 2023

Expiration Date

June 2, 2022


All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Antonello Punturieri, MD, PhD
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0233
Email: punturieria@nhlbi.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices